Breaking News

Tweet TWEET

/ CORRECTION - Flamel Technologies Announces Acceptance of FDA Review for Second NDA

/ CORRECTION - Flamel Technologies Announces Acceptance of FDA Review for 
Second NDA 
LYON, FRANCE -- (Marketwired) -- 09/11/13 --  In the news release,
"Flamel Technologies Announces Acceptance of FDA Review for Second
NDA," issued earlier today by Flamel Technologies (NASDAQ: FLML), we
are advised by the company that the second sentence of the first
paragraph should read "Flamel has received a Prescription Drug User
Fee Act (PDUFA) date, the target date for the FDA to complete its
review of the NDA, of April 28, 2014." rather than "Flamel has
received a Prescription Drug User Fee Act (PDUFA) date, the target
date for the FDA to complete its review of the NDA, of April 28,
2013." as originally issued. Complete corrected text follows.  
Flamel Technologies Announces Acceptance of FDA Review for Second NDA 
LYON, FRANCE -- Sep 11, 2013 - Flamel Technologies S.A. (NASDAQ:
FLML) today announced that the US Food and Drug Administration (FDA)
has accepted for review the Company's second new drug application
(NDA). Flamel has received a Prescription Drug User Fee Act (PDUFA)
date, the target date for the FDA to complete its review of the NDA,
of April 28, 2014. For competitive reasons, the Company has decided
not to identify the product at this time, but intends to provide
additional information at a later date.  
About Flamel Technologies. Flamel Technologies SA's (NASDAQ: FLML)
business model is to blend high-value internally developed products
with its leading drug delivery capabilities. The Company has a
proprietary pipeline of niche specialty pharmaceutical products,
while its drug delivery platforms are focused on the goal of
developing safer, more efficacious formulations of drugs to address
unmet medical needs. Its partnered pipeline includes biological and
chemical drugs formulated with its Medusa(R) and Micropump(R) (and
its applications to the development of liquid formulations, i.e.
LiquiTime(TM) and of abuse-deterrent formulations Trigger Lock(TM))
proprietary drug delivery platforms. Several Medusa-based products
have been successfully tested in clinical trials. The Company has
developed products and manufactures Micropump-based microparticles
under FDA-audited GMP guidelines. Flamel Technologies has
collaborations with a number of leading pharmaceutical and
biotechnology companies, including GlaxoSmithKline (Coreg CR(R),
carvedilol phosphate). The Company is headquartered in Lyon, France
and has operations in St. Louis, Missouri, USA, and manufacturing
facilities in Pessac, France. Additional information may be found at
www.flamel.com. 
Safe Harbor 
 This release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of
1995, including certain plans, expectations, goals and projections
regarding financial results, product developments and technology
platforms. All statements that are not clearly historical in nature
are forward-looking, and the words "anticipate," "assume," "believe,"
"expect," "estimate," "plan," "will," "may," and similar expressions
are generally intended to identify forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control that could cause
actual results to differ materially from those contemplated in such
forward-looking statements. These risks include risks that the
continued integration of Eclat Pharmaceuticals may not be successful
or that certain payment acceleration events may be triggered; the
reacquisition of the exclusive rights to develop and commercialize
IFN-β XL worldwide and identification of an alternative
strategic partner for the program may not be successful; the
identified opportunities will not result in shorter-term, high value
results; clinical trial results may not be positive or our partners
may decide not to move forward; products in the development stage may
not achieve scientific objectives or milestones or meet stringent
regulatory requirements; products in development may not achieve
market acceptance; competitive products and pricing may hinder our
commercial opportunities; we may not be successful in identifying and
pursuing opportunities to develop our own product portfolio using
Flamel's technology; and the risks associated with our reliance on
outside parties and key strategic alliances. These and other risks
are described more fully in Flamel's Annual Report on Form 20-F for
the year ended December 31, 2012 that has been filed with the
Securities and Exchange Commission (SEC). All forward-looking
statements included in this release are based on information
available at the time of the release. We undertake no obligation to
update or alter our forward-looking statements as a result of new
information, future events or otherwise. 
Investor Contact:
Bob Yedid 
ICR Inc.
(646) 277-1250
bob.yedid@icrinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.